{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:51:26Z","timestamp":1784692286250,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04542-0","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:22:08Z","timestamp":1762960928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Spectrum and outcomes of thrombotic microangiopathies in nephrology: a 17-year cohort from a North African center"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-5422","authenticated-orcid":false,"given":"Sanda","family":"Mrabet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Dardour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Boukadida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidina","family":"Emah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissal","family":"Sahtout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorsaf","family":"Zellama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"7","key":"4542_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654\u201366.","journal-title":"N Engl J Med"},{"issue":"3","key":"4542_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/ckj\/sfz040","volume":"12","author":"C Aigner","year":"2019","unstructured":"Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. Updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated TMA. Clin Kidney J. 2019;12(3):333\u20137. https:\/\/doi.org\/10.1093\/ckj\/sfz040.","journal-title":"Clin Kidney J"},{"issue":"1","key":"4542_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/187152909787581318","volume":"9","author":"P Coppo","year":"2009","unstructured":"Coppo P, Veyradier A. Thrombotic microangiopathies: towards a pathophysiology-based classification. Cardiovasc Hematol Disord Drug Targets. 2009;9(1):36\u201350.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"17","key":"4542_CR4","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676\u201387.","journal-title":"N Engl J Med"},{"key":"4542_CR5","doi-asserted-by":"crossref","unstructured":"KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2021;99(3S):S1\u201387.","DOI":"10.1016\/j.kint.2020.11.003"},{"issue":"1","key":"4542_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease","year":"2012","unstructured":"Kidney Disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1\u2013138.","journal-title":"Kidney Int Suppl"},{"key":"4542_CR7","doi-asserted-by":"crossref","unstructured":"Levey AS, Eckardt KU, Dorman NM et al. Nomenclature for kidney function and disease: executive summary and glossary from a KDIGO consensus conference. Eur Heart J. 2020;41(48):4592\u20138.","DOI":"10.1093\/eurheartj\/ehaa650"},{"key":"4542_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf091","author":"J Morelle","year":"2025","unstructured":"Morelle J, Caravaca-Fontan F, Fakhouri F, et al. Complement activation in secondary thrombotic microangiopathies. Nephrol Dial Transpl. 2025. https:\/\/doi.org\/10.1093\/ndt\/gfaf091.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"4542_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","volume":"106","author":"M Vivarelli","year":"2024","unstructured":"Vivarelli M, Barratt J, Beck LH Jr, et al. The role of complement in kidney disease: conclusions from a KDIGO controversies conference. Kidney Int. 2024;106(3):369\u201391. https:\/\/doi.org\/10.1016\/j.kint.2024.05.015.","journal-title":"Kidney Int"},{"issue":"10","key":"4542_CR10","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/jth.15006","volume":"18","author":"M Scully","year":"2020","unstructured":"Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga JA, et al. International society on thrombosis and haemostasis guidelines for diagnosis and management of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2486\u201395.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"4542_CR11","first-page":"529","volume":"33","author":"JB Arlet","year":"2013","unstructured":"Arlet JB, Vigneau C, Rondeau E. Thrombotic microangiopathy and kidney disease. Semin Nephrol. 2013;33(6):529\u201339.","journal-title":"Semin Nephrol"},{"issue":"10","key":"4542_CR12","first-page":"1579","volume":"5","author":"CM Zattra","year":"2020","unstructured":"Zattra CM, Ronsin C, Canaud G, Dussol B, Burtey S. Renal pathology in African countries: challenges and future perspectives. Kidney Int Rep. 2020;5(10):1579\u201388.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"4542_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D. Thro\u00b5botic \u00b5icroangiopathy and the kidney. Clin J A\u00b5 Soc Nephrol. 2018;13(2):300\u201317.","journal-title":"Clin J A\u00b5 Soc Nephrol"},{"issue":"3","key":"4542_CR14","first-page":"283","volume":"121","author":"M Palomo","year":"2021","unstructured":"Palomo M, Blasco M, Molina P, Martinez-Sanchez J, Diaz-Ricart M. Complement activation and thrombotic microangiopathy: an updated review. Thromb Haemost. 2021;121(3):283\u201396.","journal-title":"Thromb Haemost"},{"issue":"6","key":"4542_CR15","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"CM Nester","year":"2013","unstructured":"Nester CM, Smith RJ. Complement Inhibition in atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508\u201316.","journal-title":"Semin Nephrol"},{"issue":"7","key":"4542_CR16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ncpneuro0237","volume":"2","author":"BJ van den Born","year":"2006","unstructured":"van den Born BJ, Koopmans RP, Groeneveld JO, van Montfrans GA. Malignant hypertension: diagnosis and therapy. Nat Rev Nephrol. 2006;2(7):375\u201384.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"4542_CR17","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/ndt\/gfac248","volume":"38","author":"T Cavero","year":"2023","unstructured":"Cavero T, Au\u00f1\u00f3n P, Caravaca-Font\u00e1n F, Trujillo H, Arjona E, Morales E, et al. Thrombotic microangiopathy in patients with malignant hypertension. Nephrol Dial Transpl. 2023;38(5):1217\u201326.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4542_CR18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1081\/PRG-120016791","volume":"22","author":"JN Martin Jr","year":"2003","unstructured":"Martin JN Jr, Brewer JM, Blake PG, Owens MT, Sparks RA, Files JC, et al. HELLP syndrome: clinical characteristics and maternal mortality. Hypertens Pregnancy. 2003;22(1):25\u201331.","journal-title":"Hypertens Pregnancy"},{"issue":"2","key":"4542_CR19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.kint.2020.12.002","volume":"99","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Scully M. Management of thrombotic microangiopathy in pregnancy and postpartum. Kidney Int. 2021;99(2):277\u201388.","journal-title":"Kidney Int"},{"issue":"4","key":"4542_CR20","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125(4):616\u20138.","journal-title":"Blood"},{"issue":"5","key":"4542_CR21","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1111\/bcp.15631","volume":"89","author":"S Mrabet","year":"2023","unstructured":"Mrabet S, Dahmane R, Raja B, Othmen MB, Sfar H, Zouari B, et al. Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon-beta treatment for multiple sclerosis. Br J Clin Pharmacol. 2023;89(5):1682\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4542_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/1744-9987.12763","volume":"23","author":"R Raina","year":"2019","unstructured":"Raina R, Krishnappa V, Blaha T, Kann T, Kim S, Sharma S, et al. Atypical hemolytic uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4\u201321.","journal-title":"Ther Apher Dial"},{"issue":"23","key":"4542_CR23","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381.","journal-title":"N Engl J Med"},{"issue":"1","key":"4542_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"4542_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Coppo R, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15\u201339.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"4542_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/ckj\/sfac224","volume":"16","author":"V Brglez","year":"2023","unstructured":"Brglez V, Stojanovic J, Artic M, Kouter D, Kenda RB, Buturovic-Ponikvar J, et al. Real-life outcomes of TMA management in low-income countries. Clin Kidney J. 2023;16(2):205\u201313.","journal-title":"Clin Kidney J"},{"issue":"2","key":"4542_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga JA, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312\u201322.","journal-title":"J Thromb Haemost"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04542-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04542-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04542-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:22:11Z","timestamp":1762960931000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04542-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4542"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04542-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Sahloul University Hospital of Sousse (Reference number: HS 16-2025). Individual patient consent was not required, as the study relied exclusively on anonymized data extracted from medical records. This is in accordance with Tunisian legislation, specifically the \u201cArr\u00eat\u00e9 du Ministre de la Sant\u00e9 du 13 janvier 2015\u201d, which exempts retrospective studies using anonymized data from requiring informed consent when approved by an ethics committe. All authors approved the manuscript and gave their consent for submission and publication. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"631"}}